false
0001574094
0001574094
2026-11-20
2026-11-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 20, 2026 (November 18, 2026)
RENOVORX,
INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-40738 |
|
27-1448452 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2570
W El Camino Real, Suite 640
Mountain
View, CA |
|
94040 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (650) 284-4433
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instructions A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.0001 par value per share |
|
RNXT |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Appointment
of Richard Stark as a Director
Effective
as of November 18, 2026, the Board of Directors (the “Board”) of RenovoRx, Inc., a Delaware corporation (the “Company”),
approved an increase the size of the Board from six directors to seven directors and appointed Richard Stark to fill the vacancy on the
Board occasioned by such increase (the “Appointment”).
The
following is certain biographical information regarding Mr. Stark:
Richard
Stark, age 62, has more than 30 years of leadership experience in the medical technology industry. Since January 2024, he has served
as Founder and Managing Member of MedTech Angels, an investment group focused on early-stage medical technology companies. Since January
2021, he has served as Chief Executive Officer of Innoblative Designs, Inc., a medical technology company developing advanced radiofrequency
ablation technologies. Since January 2017, he has served as Founder and Principal of RAS Consulting Firm, LLC, advising healthcare companies,
boards of directors and investors on commercialization strategy, business development, fundraising, strategic partnerships, mergers and
acquisitions, and corporate growth initiatives. Previously, Mr. Stark served as Chief Executive Officer, President, and a member of the
board of directors of Sanarus Technologies, a medical device company, from January 2018 to January 2021, where he led the company through
the strategic transfer of its technology assets to Hologic, Inc. Prior to Sanarus, he served at AngioDynamics (Nasdaq: ANGO), a medical
technology company, as Senior Vice President and General Manager, Global Oncology/Surgery, from January 2010 to January 2018 and as General
Manager and Vice President, Sales & Marketing, Oncology/Surgery from January 2007 to January 2010. Earlier in his career, he held
senior commercial leadership positions at RITA Medical Systems from January 1999 to January 2007 and leadership roles at Woodside Biomedical
and Arrow International from January 1994 to January 1999. Mr. Stark currently serves on the boards of two medical device companies,
Pleural Dynamics and Polyembo. Mr. Stark is qualified to serve as a director due to his extensive executive leadership experience, significant
board and governance experience, deep knowledge of the medical technology sector, and demonstrated track record of driving growth, innovation,
and strategic transactions across healthcare organizations.
The
Board has determined that Mr. Stark qualifies as an independent director in accordance with the requirements of the Nasdaq Stock Market
LLC. Mr. Stark has no family relationships with any of the Company’s directors or executive officers, and he is not a party to,
and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K.
There are no arrangements or understandings between Mr. Stark and any other persons pursuant to which he was selected as a director.
Prior
to the Appointment, Mr. Stark had served as a consultant to the Company since December 5, 2024. In connection therewith, Mr. Stark provided
strategic commercial advisory services to the Company as its Strategic Commercial Advisor pursuant to a Consulting Agreement, dated as
of December 5, 2024, by and between the Company and Mr. Stark (as amended, the “Consulting Agreement”), as compensation for
which Mr. Stark received solely options to purchase shares of the Company’s common stock (the “Common Stock”) granted
under the Company’s Amended and Restated 2021 Omnibus Equity Incentive Plan (collectively, the “Consulting Options”)
and no cash compensation. On November 11, 2026, the Company and Mr. Stark entered into a Consulting Termination Agreement pursuant to
which the Consulting Agreement terminated effective as of November 15, 2026, and pursuant to which unvested Consulting Options to purchase
12,000 shares of Common Stock were forfeited by Mr. Stark.
Upon
the Appointment, pursuant to Outside Director Compensation Policy of the Company (as amended, the “Policy”), on November
18, 2026, Mr. Stark was awarded 128,824 options to purchase shares of Common Stock having a grant date fair value of $120,000
in the aggregate (the “Initial Award”), with 1/36th of the Initial Award vesting each month on the same day of the month
as the commencement of his service as an outside director, subject to his continued service through each vesting date. The Initial Award
has a per share exercise price equal $1.12, the closing price of the Common Stock on the grant date, a term of ten years, and
will vest in full upon a change in control of the Company, subject to his continued service through such date. In addition, pursuant
to the Policy, Mr. Stark will (i) receive an annual cash retainer of $40,000, payable quarterly in arrears and prorated for any partial
quarter of service, (ii) be eligible to receive the additional annual cash fees provided under the Policy for service as a chair or member
of any committee of the Board to which he may be appointed, and (iii) on October 1, 2027, be automatically granted options to purchase
shares of Common Stock having a grant date fair value of $70,000 in the aggregate, prorated based on the number of days elapsed from
November 18, 2026 until October 1, 2027, with 1/12th of such award vesting monthly on the first day of each month thereafter, subject
to his continued service. Thereafter, Mr. Stark will be eligible to receive the same compensation payable under the Policy to the Company’s
other non-employee directors. Mr. Stark will also be reimbursed for his reasonable, customary and documented travel expenses to attend
meetings of the Board and its committees.
On
November 19, 2026, the Company issued a press release announcing the Appointment, a copy of which is filed as Exhibit 99.1 to
this Form 8-K and is incorporated by reference herein.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press
Release, dated November 19, 2026, regarding the appointment of Richard Stark to the Board. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL Document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
RENOVORX,
INC. |
| Date:
November 20, 2026 |
|
|
| |
|
|
| |
By: |
/s/
Shaun R. Bagai |
| |
Name: |
Shaun
R. Bagai |
| |
Title: |
Chief
Executive Officer |
Exhibit 99.1

RenovoRx
Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors
MOUNTAIN
VIEW, Calif. – November 19, 2026 – RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT),
a life sciences company commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, and evaluating
a novel targeted oncology drug-device product candidate, today announced the appointment of Richard A. Stark, Chief Executive Officer
of Innoblative Designs, Inc., to the Company’s Board of Directors.
Mr.
Stark brings more than three decades of leadership experience in medical technology to the RenovoRx Board, with a focus on setting and
executing commercialization strategies of interventional oncology medical technologies. He has advised RenovoRx since late 2024, helping
its commercial team lay the foundation for the Company’s commercial efforts. He now brings his expertise and knowledge of the RenovoRx’s
TAMP™ (Trans-Arterial Micro-Perfusion) platform, enabled by RenovoCath, to the Company’s Board as RenovoRx continues
to gain traction in the market and physician adoption across U.S. cancer centers.
“We
are pleased to welcome Rick to our Board of Directors,” said Shaun Bagai, Chief Executive Officer of RenovoRx. “Beyond his
decades of experience in medtech sales and marketing, Rick has been instrumental in building the infrastructure that is accelerating
physician adoption of RenovoCath in interventional oncology, and his insight sharpened our commercial approach at a critical juncture.
As our market penetration across cancer centers deepens, his boardroom perspective will be important in continuing to shape our commercial
strategy and guiding how we scale.”
Mr.
Stark currently serves as Chief Executive Officer of Innoblative Designs, Inc., a medical technology company developing an RFA electrosurgical
platform for intraoperative soft-tissue coagulation and ablation, including development programs in breast-conserving surgery. He is
also Founder and Principal of RAS Consulting Firm, LLC, which advises medical technology companies on commercialization strategy, and
Founder and Managing Member of MedTech Angels, a physician and executive-led angel investment group focused on medical technology. He
serves as an independent director of Pleural Dynamics and Polyembo.
“I
have spent my career working with oncologists and other physicians to adopt technologies that deliver therapy with greater precision,
and I believe RenovoRx is well positioned with RenovoCath at the intersection of innovation and patient impact,” said Mr. Stark.
“Having worked as an advisor to the commercial team for nearly two years, I have seen the TAMP platform’s strength firsthand,
and I am excited to continue to contribute my experience as a Board member as the Company builds on its innovative approach to targeted
therapeutic delivery for patients with difficult-to-treat solid tumors.”
About
RenovoCath
Based
on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic
and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion
in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding
our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-H-Universal-IFU.pdf.
About
RenovoRx, Inc.
RenovoRx,
Inc. (Nasdaq: RNXT) is a life sciences company commercializing RenovoCath®, a novel, FDA-cleared device for local drug delivery
designed to address significant unmet medical needs, with a focus on difficult-to-treat tumors. The Company is also evaluating intra-arterial
gemcitabine (IAG) delivered via RenovoCath using RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) platform as a novel
drug-device product candidate for locally advanced pancreatic cancer.
RenovoRx’s
patented TAMP™ platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the
target tumor, potentially improving safety, tolerance, and efficacy while minimizing the toxicities associated with systemic intravenous
therapy. The Company’s mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted
delivery of diagnostic and therapeutic agents.
RenovoRx
completed enrollment in the Phase III TIGeR-PaC clinical trial in August 2026, and anticipates the initial topline data in the second
half of 2027. The trial is evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered
via RenovoCath (IAG). RenovoCath enables IAG, and is FDA-cleared for temporary vessel occlusion in applications including arteriography,
preoperative occlusion, and chemotherapeutic drug infusion. IAG is currently under investigation and has not been approved for commercial
sale.
RenovoCath
with gemcitabine received Orphan Drug Designation (ODD) for pancreatic cancer and bile duct cancer, and oxaliplatin has received ODD
for pancreatic cancer, each of which provides seven years of market exclusivity upon new drug application approval by the FDA.
For
more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary
Note Regarding Forward-Looking Statements
This
press release and statements of the Company’s management and third parties made in connection therewith contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including
but not limited to statements regarding the anticipated benefits to the Company of the appointment of Mr. Stark to the Company’s
Board of Directors as described herein as well as (i) our clinical trials and studies (including expectations for trial completion and
data read out), (ii) the potential for our product candidates and our TAMP technology (enabled by RenovoCath) to treat or provide clinically
meaningful outcomes for certain medical conditions or diseases, (iii) our efforts to commercialize our RenovoCath and TAMP technology
for use in treating pancreatic and other solid tumor cancers, and (iv) our expected financial results from such efforts, including our
estimates for 2026 annual revenue and anticipated active commercial sites, as well as statements regarding our cash runway. Statements
that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current
expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and
involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements
relating to our commercial and other business plans, objectives and strategies, our research and development plans, intellectual property
development, clinical trials, our therapy platform, financing plans, and expected operating results, all of which are based on current
expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results
to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified
using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,”
“forecasts,” “aim,” “goal,” “estimates,” “future,” “intends,”
and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about
the future, although not all forward-looking statements contain these words. All forward-looking statements are subject to a number of
risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements,
including, among other things: (i) the risk that our commercial efforts for our TAMP technology (enabled by RenovoCath) may not lead
to the achievement of our revenue forecasts or to viable, revenue generating operations in general or to the achievement of the number
of active cancer center customers we expect; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash
resources on hand or raise additional funding; (iii) the timing of the initiation, progress, completion and potential results (including
the results of interim analyses and final trial data) of our preclinical studies, clinical trials, and our research programs (notably
with respect to our Phase III TIGeR-PaC trial); (iv) the possibility that interim results may not be predictive of the outcome of our
clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v)
that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and
timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates,
including those related to current and planned clinical studies; (vii) our ability to use and expand our TAMP therapy platform for drug-delivery
to treat other forms of cancer or to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and
successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number
of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the
commercialization potential of RenovoCath as a standalone device or our product candidates, if such product candidates are approved by
the FDA; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for
commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements;
(xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional
capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents
to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our
key personnel and to identify, hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish
and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xviii) our
ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage,
and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including
competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled
“Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed
at https://ir.renovorx.com/sec-filings.
As
a result of the foregoing, you are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements included
herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements
to reflect subsequent events or circumstances, except as required by law.
Investor
Contact:
ICR
Healthcare
Stephanie
Carrington or Adanna G. Alexander, Ph.D.
T:
646-277-1282
Renovorx@icrhealthcare.com
Media
Contact:
STiR
Communications
Hannah
Williams
T:
803-521-1214
hannah@stir-communications.com